Hepatocellular Carcinoma: Clinical Insights on Expanding Systemic Treatment Options

Register Now

Join CCO’s distinguished faculty for a CME-certified satellite symposium on optimal care for patients with advanced HCC, including current therapy options and individualizing treatment based on patient and disease characteristics, as well as promising investigational targeted therapies and immune checkpoint inhibitors.

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.


Approved Systemic Therapies for Advanced HCC
Tanios Bekaii-Saab, MD

Emerging Molecular Targets and Novel Targeted Therapeutic Options for Advanced HCC
Peter R. Galle, MD

Immune Checkpoint Inhibitors for Advanced HCC
Tim F. Greten, MD

Closing Remarks and Audience Question and Answer Session
Tanios Bekaii-Saab, MD


Date / Time
Event Details


Program Chair
Tanios Bekaii-Saab, MD, FACP

Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Peter Galle, MD

First Department of Internal Medicine
University Medical Center
Mainz, Germany

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hematology
Hannover Medical School
Hannover, Germany


Program Overview
Join us at ASCO 2017 for a CME-certified satellite symposium on HCC focused on recent developments regarding systemic therapy, individualizing treatment, and a look at promising investigational agents with the potential to change clinical practice.

Goal Statement
The goal of this activity is to improve participants’ competence in and performance at applying evidence-based systemic therapy approaches to optimize clinical outcomes for patients with metastatic hepatocellular carcinoma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with hepatocellular carcinoma.

Learning Objectives

  • Gain insight on therapeutic strategies to maximize the efficacy of sorafenib in advanced HCC
  • Evaluate the therapeutic impact of regorafenib in patients with HCC and disease progression after first-line treatment with sorafenib
  • Consider the biologic rationale and the efficacy and safety evidence for molecularly targeted agents in advanced HCC
  • Incorporate novel agents and clinical trial participation as part of clinical care strategies for HCC
  • Differentiate the mechanisms of action and scientific rationale for the use of immunotherapy approaches in HCC
  • Evaluate the efficacy and safety data on immune checkpoint inhibitors for the treatment of HCC


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.